RemeGen Entered into a Clinical Research Agreement with Innovent to Evaluate RC88 and RC108 Combined with Tyvyt (sintilimab) for Advanced Solid Tumors
- The companies collaborated to conduct the P-I/IIa clinical trial evaluating the safety, tolerability & preliminary efficacy of RC88 or RC108 combined with sintilimab in cancer patients
- Innovent will lead the clinical drug supplies of sintilimab. RC88 monotx. exhibits anti-tumor activity in preliminary studies against MSLN-expressing solid tumors and demonstrated manageable safety while RC108 induces tumor-specific adaptive immunity in preclinical research, and enhances T-cell infiltration in the tumor microenvironment
- RC88 with ICIs i.e., PD-1/PD-L1 can induce ICD releasing a series of signaling molecules that activate T cells & improve the tumor immune response
Ref: PRNewswire | Image: RemeGen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.